Nutrition, metabolism, and cardiovascular diseases : NMCD
Combined SGLT2i and GLP1ra therapy reduces all-cause mortality in people with diabetes, with greater benefit in women.
David Garcia-Vega, Sergio Cinza-Sanjurjo, Carlos Tilves-Bellas, Sonia Eiras, José Ramón González-Juanatey
Published: 202510.1016/j.numecd.2025.104483
Abstract
BACKGROUND AND AIMS: Combined therapy, sodium-glucose cotransporter 2 inhibitors (SGLT2i), and glucagon-like peptide-1 receptor agonists (GLP1ra) reduce all-cause mortality in patients with diabetes. We aimed to analyse the differential behaviour of…
Preview only. Read the full abstract at the source